Association of Genetic Variants of Dopamine and Serotonin In Schizophrenia.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Science Country of Publication: United States NLM ID: 9312706 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5487 (Electronic) Linking ISSN: 01884409 NLM ISO Abbreviation: Arch Med Res Subsets: MEDLINE
    • Publication Information:
      Publication: 1999- : New York, NY : Elsevier Science
      Original Publication: Mexico, D.F. : Instituto Mexicano del Seguro Social, [1992-
    • Subject Terms:
      Polymorphism, Single Nucleotide*; Catechol O-Methyltransferase/*genetics ; Cytochrome P-450 CYP2D6/*genetics ; Receptors, Dopamine/*genetics ; Receptors, Serotonin/*genetics ; Schizophrenia/*genetics; Adult ; Aged ; Antipsychotic Agents/therapeutic use ; Case-Control Studies ; Dopamine/genetics ; Dopamine/metabolism ; Female ; Gene Frequency ; Genetic Association Studies ; Genetic Predisposition to Disease ; Genotype ; Humans ; Male ; Metabolic Networks and Pathways/genetics ; Middle Aged ; Schizophrenia/drug therapy ; Serotonin/genetics ; Serotonin/metabolism ; Young Adult
    • Abstract:
      Background: Several studies indicated that antipsychotic treatment response and side effect manifestation can be different due to inter-individual variability in genetic variations.
      Aim of the Study: Here we perform a case-control study to explore a potential association between schizophrenia and variants within the antipsychotic drug molecular targets (DRD1, DRD2, DRD3, HTR2A, HTR6) and metabolizing enzymes (CYP2D6, COMT) genes in Armenian population including also analysis of their possible relationship with disease clinical symptoms.
      Methods: A total of 18 SNPs was studied in patients with schizophrenia (n = 78) and healthy control subjects (n = 77) using MassARRAY genotyping.
      Results: We found that two studied genetic variants, namely DRD2 rs4436578*C and HTR2A rs6314*A are underrepresented in the group of patients compared to healthy subjects. After the correction for multiple testing, the rs4436578*C variant remained significant while the rs6314*A reported borderline significance. No significant differences in minor allele frequencies for other studied variants were identified. Also, a relationship between the genotypes and age of onset as well as disease duration has been detected.
      Conclusions: The DRD2 rs4436578*C genetic variant might have protective role against schizophrenia, at least in Armenians.
      (Copyright © 2019 IMSS. Published by Elsevier Inc. All rights reserved.)
    • Contributed Indexing:
      Keywords: Antipsychotic treatment; Association; Dopamine; Genetic variant; Metabolizing enzyme; Schizophrenia; Serotonin
    • Accession Number:
      0 (Antipsychotic Agents)
      0 (Receptors, Dopamine)
      0 (Receptors, Serotonin)
      333DO1RDJY (Serotonin)
      EC 1.14.14.1 (Cytochrome P-450 CYP2D6)
      EC 2.1.1.6 (COMT protein, human)
      EC 2.1.1.6 (Catechol O-Methyltransferase)
      VTD58H1Z2X (Dopamine)
    • Publication Date:
      Date Created: 20200223 Date Completed: 20200727 Latest Revision: 20200727
    • Publication Date:
      20231215
    • Accession Number:
      10.1016/j.arcmed.2019.12.011
    • Accession Number:
      32086104